Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

Show full item record



Permalink

http://hdl.handle.net/10138/323572

Citation

Hjortshoj , C S , Gilljam , T , Dellgren , G , Pentikainen , M O , Moller , T , Jensen , A S , Turanlahti , M , Thilen , U , Gustafsson , F & Sondergaard , L 2020 , ' Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome ' , Heart , vol. 106 , no. 2 , pp. 127-132 . https://doi.org/10.1136/heartjnl-2019-315345

Title: Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome
Author: Hjortshoj, Cristel S.; Gilljam, Thomas; Dellgren, Goran; Pentikainen, Markku O.; Moller, Thomas; Jensen, Annette Schophuus; Turanlahti, Maila; Thilen, Ulf; Gustafsson, Finn; Sondergaard, Lars
Contributor: University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Children and Adolescents
Date: 2020-01
Language: eng
Number of pages: 6
Belongs to series: Heart
ISSN: 1355-6037
URI: http://hdl.handle.net/10138/323572
Abstract: Objective The optimal timing for transplantation is unclear in patients with Eisenmenger syndrome (ES). We investigated post-transplantation survival and transplantation-specific morbidity after heart-lung transplantation (HLTx) or lung transplantation (LTx) in a cohort of Nordic patients with ES to aid decision-making for scheduling transplantation. Methods We performed a retrospective, descriptive, population-based study of patients with ES who underwent transplantation from 1985 to 2012. Results Among 714 patients with ES in the Nordic region, 63 (9%) underwent transplantation. The median age at transplantation was 31.9 (IQR 21.1-42.3) years. Within 30 days after transplantation, seven patients (11%) died. The median survival was 12.0 (95% CI 7.6 to 16.4) years and the overall 1-year, 5-year, 10-year and 15-year survival rates were 84.1%, 69.7%, 55.8% and 40.6%, respectively. For patients alive 1 year post-transplantation, the median conditional survival was 14.8 years (95% CI 8.0 to 21.8), with 5-year, 10-year and 15-year survival rates of 83.3%, 67.2% and 50.0%, respectively. There was no difference in median survival after HLTx (n=57) and LTx (n=6) (14.9 vs 10.6 years, p=0.718). Median cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis/kidney transplantation-free survival rates were 11.2 (95% CI 7.8 to 14.6), 6.9 (95% CI 2.6 to 11.1) and 11.2 (95% CI 8.8 to 13.7) years, respectively. The leading causes of death after the perioperative period were infection (36.7%), bronchiolitis obliterans syndrome (23.3%) and heart failure (13.3%). Conclusions This study shows that satisfactory post-transplantation survival, comparable with contemporary HTx and LTx data, without severe comorbidities such as cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis, is achievable in patients with ES, with a conditional survival of nearly 15 years.
Subject: 3121 General medicine, internal medicine and other clinical medicine
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
127.full.pdf 398.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record